Pfizer Inc. (PFE) — closed signal from July 3, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 1, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published July 3, 2025
Pfizer offers a hefty 6.2% yearly cash payout, which many investors see as a cushion if the share price wobbles. On July 3 the US drug watchdog cleared its new RSV shot, adding fresh sales, while another heart-lung medicine is on a fast review track. After drifting for over a year the stock finally rose above its longer-term average price, hinting at improving momentum. Income hunters often move into high-dividend names before earnings, so a slide back toward the mid-$24 area could set up a three-month bounce.
Primary drivers
- July 3 approval of an RSV vaccine adds a new revenue stream to Pfizer’s shot lineup.
- Fast-track review for WINREVAIR may open a multi-billion lung-disease market by 2026.
- A $4 billion cost-cutting plan should lift 2025 profits and free up more cash.
- A 6.2% yield and shares at 10× 2025 profit lure income seekers on pullbacks.
How it played out
PFE: target was cleared by the window end
Lyra published PFE at $24.46 on July 3, with 12% expected growth and a $26.46 target. The thesis pointed to a 6.2% yearly cash payout, July 3 clearance for an RSV shot, fast review for WINREVAIR, a $4 billion cost-cutting plan, and shares at 10x 2025 profit.
Inside the July 3 to October 1 window, PFE rose to a $26.98 peak on October 1. That was above the $26.46 target, although the data did not give a day count for reaching it. The stock ended at $26.74, with a 10.3% peak gain. The thesis played out.
What happened during the window
On September 22, 2025, Pfizer announced a deal to acquire Metsera for an initial $4.9 billion, with possible additional payments tied to development milestones. On September 30, 2025, Pfizer and the U.S. government announced a drug-pricing agreement tied to Medicaid pricing, direct purchasing, and a stated $70 billion investment plan.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.